UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/582,640	04/20/2007	Alexander Mackerell	100413-5018	1522

9629 7590 12/30/2010

MORGAN LEWIS & BOCKIUS LLP
1111 PENNSYLVANIA AVENUE NW
WASHINGTON, DC 20004

EXAMINER	
POLANSKY, GREGG	
ART UNIT	PAPER NUMBER
1614	
MAIL DATE	DELIVERY MODE
12/30/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/582,640	MACKERELL ET AL.	
	Examiner	Art Unit	
	GREGG POLANSKY	1614	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE *3* MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *28 October 2010*.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *1-23* is/are pending in the application.

4a) Of the above claim(s) *3-6,9,14-17,20 and 23* is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *1,2,7,8,10-13,18,19,21 and 22* is/are rejected.

7)☒ Claim(s) *1,2,12,13,18,19,21 and 22* is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☒ The specification is objected to by the Examiner.

10)☒ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☒ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date *6/12/2006*.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .
5) ☐ Notice of Informal Patent Application
6) ☐ Other: _____.

DETAILED ACTION

Status of Claims

1. Applicants' preliminary amendment of the Specification, filed 4/28/2006, is acknowledged.

2. Applicants' Information Disclosure Statement, filed 6/12/2006, is acknowledged and has been reviewed.

3. Applicant's election **without traverse** of Group I (claims drawn to instant formula (I)) in the reply filed on 7/28/2010 is acknowledged. The Restriction Requirement is thus deemed to be proper and is made **Final**.

4. Applicants' election of species in papers filed 10/28/2010 is acknowledged. Applicants elected a compound of formula (I) wherein **B** is a phenyl ring; **D** is a phenyl ring; **A** associated with $\mathbf{Z_3}$ is a 5-membered unsaturated heterocyclic ring containing one O; **A** associated with $\mathbf{Z_1}$ is a 5-membered heterocyclic ring containing one S and one N; **Q** is an alkenylene group with 3 carbon atoms, substituted with =O, and a carbon atom is replaced with an N; $\mathbf{(Z_1)_n}$ where **n** is 2 and $\mathbf{Z_1}$ is =O; $\mathbf{(Z_2)_n}$ associated with **B** where **n** is 2, $\mathbf{Z_2}$ is methyl for one substituent, and for another substituent, methyl substituted with =O and OH; $\mathbf{(Z_2)_n}$ associated with **D** where **n** is 1, $\mathbf{Z_2}$ is methyl; and $\mathbf{(Z_3)_n}$ wherein **n** is 0. Applicants did not explicitly recite a specific, disclosed compound; however instantly disclosed compound # 276 reads on formula (I) having the above variable assignments. Therefore compound # 276 is presently under examination. Applicants further elected an inhibitory effect on hyperproliferative cell growth as the elected therapeutic effect specie. Because Applicants did not distinctly and specifically point out the supposed

errors in the election of species requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). The Restriction Requirement is thus deemed to be proper and is made **Final**.

5. Claims 1-23 are pending.

6. Claims 3-6, 9, 14-17, 20 and 23 are withdrawn from consideration in accordance with 37 CFR 1.142(b), because they are contained in non-elected groups and/or are drawn to non-elected species.

7. Claims 1, 2, 7, 8, 10-13, 18, 19, 21 and 22 are presently under consideration.

Drawings

8. The drawings are objected to because the quality of Fig. 1 is such that it cannot be clearly read and interpreted. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as "amended." If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either

"Replacement Sheet" or "New Sheet" pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.

Specification

9. The disclosure is objected to because of the following: At line 7 of the 2nd paragraph at page 152, the phrase "*in vivo*" should be "*in vitro*".

Appropriate correction is required.

Claim Objections

10. Claims 1, 2, 12, 13, 18, 19, 21 and 22 are objected to because they recite formulae or compounds that are not in elected Group I.

11. Claim 1 is objected to because of the following informalities: The word "of" should be between the words "compound" and "formulae" at line 3 of the claim.

12. Claims 12 and 13 are objected to because of the following informalities: The comma and the word "or" should be removed from the end of each claim and be replaced with a period.

Claim Rejections - 35 USC § 112

13. The following is a quotation of the first paragraph of 35 U.S.C. 112:

> The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the

> art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

14. Claims 1, 7, 8, 10-12, 18 and 21 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claims contain subject matter which was not described in the Specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. This is an Enablement rejection.

To be enabling, the Specification of the patent application must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation. *In re Wright*, 999 F.2d 1557, 1561 (Fed. Cir. 1993). Explaining what is meant by "undue experimentation," the Federal Circuit has stated that:

> The test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which experimentation should proceed to enable the determination of how to practice a desired embodiment of the claimed invention. *PPG v. Guardian*, 75 F.3d 1558, 1564 (Fed. Cir. 1996). (As pointed out by the court in *In re Angstadt*, 537 F.2d 498 at 504 (CCPA 1976), the key word is “undue”, not “experimentation”)

The factors that may be considered in determining whether a disclosure would require undue experimentation are set forth by *In re Wands*, 8 USPQ2d 1400 (CAFC 1988) at 1404 wherein, citing *Ex parte Forman*, 230 USPQ 546 (Bd. Apls. 1986) at 547 the court recited eight factors:

1) the quantity of experimentation necessary,

2) the amount of direction or guidance provided,

3) the presence or absence of working examples,

4) the nature of the invention,

5) the state of the prior art,

6) the relative skill of those in the art,

7) the predictability of the art, and

8) the breadth of the claims.

These factors are always applied against the background understanding that scope of enablement varies inversely with the degree of unpredictability involved. *In re Fisher*, 57 CCPA 1099, 1108, 427 F.2d 833,839, 166 USPQ 18, 24 (1970). Keeping that in mind, the *Wands* factors are relevant to the instant fact situation for the following reasons:

1. The nature of the invention, state and predictability of the art, and relative skill of those in the art

The invention relates to a method of achieving an immunomodulatory effect, achieving an antineoplastic effect, or inhibiting hyperproliferative cell growth in a patient in need thereof, comprising administering to said patient an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.

The relative skill of those in the art is high, generally that of an M.D. or Ph.D. The artisan using Applicants' invention would generally be a physician with a M.D. degree and several years of experience.

That factor is outweighed, however, by the unpredictable nature of the art. It is well established that "the scope of enablement varies inversely with the degree of unpredictability of the factors involved" and physiological activity is generally considered to be an unpredictable factor. See *In re Fisher*, 166 USPQ 18, at 24 (In cases involving

unpredictable factors, such as most chemical reactions and physiological activity, the scope of enablement obviously varies inversely with the degree of unpredictability of the factors involved.), *Nationwide Chemical Corporation, et al. v. Wright, et al.*, 192 USPQ 95 (one skilled in chemical and biological arts cannot always reasonably predict how different chemical compounds and elements might behave under varying circumstances), *Ex parte Sudilovsky* 21 USPQ 2d 1702 (Appellant's invention concerns pharmaceutical activity. Because there is no evidence of record of analogous activity for similar compounds, the art is relatively unpredictable) *In re Wright* 27 USPQ2d 1510 (the physiological activity of RNA viruses was sufficiently unpredictable that success in developing specific avian recombinant virus vaccine was uncertain). As long as the specification discloses at least one method of making and using the claimed invention that bears a reasonable correlation to the entire scope of the claim, then the enablement requirement of 35 U.S.C. 112, 1st Paragraph is satisfied. *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). To that extent, if little is known in the prior art about the nature of the invention and the art is unpredictable, the specification would need more detail as to how to make and use the invention in order to be enabling. See *Chiron Corp v. Genetech, Inc.*, 363 F.3d 1247, 1254, 70 USPQ2d 1321, 1326 (Fed. Cir. 2004) ("Nascent technology, however, must be enabled with a specific and useful teaching. The law requires an enabling disclosure for nascent technology because a person of ordinary skill in the art has little or no knowledge independent from the patentee's instruction. Thus, the public's end of the bargain struck by the patent system is a full enabling disclosure of the claimed technology."

Hyperproliferative cell growth encompasses conditions, such as, neoplasms, hyperplasias, and benign or malignant tumors (e.g., cancers). When just considering hyperplasias, one skilled in the art would recognize many different types of hyperplasias. Hyperplasia, which is an abnormal increase in the number of cells in a tissue or organ, includes congenital adrenal hyperplasia, benign prostatic hyperplasia, C-cell hyperplasia, adrenocortical hyperplasia, cutaneous lymphoid hyperplasia, fibrous inflammatory hyperplasia, G cell hyperplasia, hepatic hyperplasia, lipoid hyperplasia, neoplastic hyperplasia, squamous hyperplasia, and verrucous hyperplasia, to name a few. See Dorland's Illustrated Medical Dictionary, 31st Edition ("Hyperplasia", Saunders Elsevier, 2007, pp. 906-907).

2. The breadth of the claims

With regard to the presently elected specie of inhibiting hyperproliferative cell growth, the invention relates to methods of inhibiting hyperproliferative cell growth in a patient, encompassing a plethora of diverse diseases (*supra*), comprising administering a compound of formula (I) (recited in Claim 1). The claimed compounds encompass a multitude (perhaps millions) of different compounds having chemically distinct substituents. Dependent Claim 12 recites 34 compounds, three of which read on formula (I) (Compounds 73, 276 and 285). Claim 18 limits the compounds of Claim 1 to those having a ClogP value of ≤ 5, a molecular weight of ≤ 500 Daltons, and ≤ 10 hydrogen bond donors and acceptors. Dependent Claims 7, 8 and 10 limit the patient population to those suffering from a neoplasm or hyperplasia (Claim 7); a benign or malignant tumor (Claim 8); or leukemia, lymphoma, ovarian cancer and breast cancer

(Claim 10). It is noted that Claim 10 requires that the patient is suffering from leukemia, lymphoma, ovarian cancer **and** breast cancer (i.e., the patient must be suffering from all the recited diseases).

Exemplary of the breadth of compounds which are defined by formula (I) are the following 2 hypothetical compounds (Compounds “A” and "B”):



Hypothetical Compound "A" of Formula (I)



Hypothetical Compound "B" of Formula (I)

Whether any particular compounds encompassed by the claims would have any activity *in vitro*, let alone *in vivo*, would require synthesis and purification of the compound followed by testing in an *in vitro* or *in vivo* assay. Predicting, *a priori*, whether a given compound will inhibit hyperproliferative cell growth does not appear to be possible.

3. The amount of direction or guidance provided and the presence or absence of working examples

The Specification discloses, at page 138, that "[h]yperproliferative cell disorders include, *e.g.*, cancers, blood vessel proliferative disorders, fibrotic disorders, and autoimmune disorders." Page 136 of the Specification states "It is proposed that compounds of the invention, by interacting with $p56^{lck}$, particularly with an SH2 domain thereof, modulate the kinase activity of the protein and/or modulate its ability to interact with a corresponding cellular binding protein, and thereby modulate immune responses, directly or indirectly, and neoplastic cell proliferation." The Specification discloses that 2 compounds of formula (I) (compounds 73 and 276) were tested in an *in vitro* assay for the inhibition of "p56 Lck SH2 domain association with phosphotyrosine-containing C-terminal ITAM2 peptide." According to the Specification, immunoblots from the assays (Figure 1-A) show compound 276 has "significant inhibitory activities at 100 μM [and] Figure 1 (panel B) shows a dose dependent inhibition of co-precipitation by the inhibitor 73; at 40 μM (lane 5) the compound significantly blocked p56 Lck association with the ITAM2 peptide. The 34 preferred compounds identified herein were shown to have significant inhibitory activity at 100 μM….Of these, compounds 73 and 92 show strong

inhibitory activity at 40 and 10 μM, respectively." (Pages 149-152) It is noted by the Examiner that only 3 (compounds 73, 276 and 285) of the 34 disclosed compounds read on formula (I) and actual data is presented for only 2 of these compounds (73 and 276). Figure 2 of the disclosure present *in vitro* data for inhibition of ^{3}H-thymidine uptake in mixed lymphocyte culture. According to the Specification (page 152), 24 of the 34 identified compounds were tested, with 13 compounds showing inhibitory activity at 100 μM concentration (shown in Figure 2). It is disclosed that compound 73 was not tested at 100 μM because of solubility issues. It is noted that only 2 compounds (compounds 73 and 276) were presented as having activity. The Specification also discloses that 7 of the compounds showed "biphasic" activity, "where positive inhibitory activity is observed at higher concentration (100 μM) and negative inhibition (i.e. activation) occurs at lower concentrations (1 μM)."

4. The quantity of experimentation necessary

Because of the known unpredictability of the art (as discussed *supra*) and in the absence of experimental evidence commensurate in scope with the claims, the skilled artisan would not accept the assertion that the instantly claimed genus of compounds could be predictably used to inhibit all (or any) types of hyperproliferative cell growth encompassed by the claims.

Genentech Inc. vs. Nova Nordisk states, "[A] patent is not a hunting license. It is not a reward for a search but a compensation for its successful conclusion and 'patent protection' is granted in return for an enabling disclosure of an invention, not for vague

intimations of general ideas that may or may not be workable" (42 USPQ 2d 1001, Fed. Circuit 1997).

Accordingly, the instant claims do not comply with the enablement requirement of 35 U.S.C. 112, first paragraph, since to practice the claimed invention a person of ordinary skill in the art would have to engage in undue experimentation, with no reasonable assurance of success.

15. Claims 2, 13, 19 and 22 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claims contain subject matter which was not described in the Specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. This is an Enablement rejection.

To be enabling, the Specification of the patent application must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation. *In re Wright*, 999 F.2d 1557, 1561 (Fed. Cir. 1993). Explaining what is meant by "undue experimentation," the Federal Circuit has stated that:

> The test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which experimentation should proceed to enable the determination of how to practice a desired embodiment of the claimed invention. *PPG v. Guardian*, 75 F.3d 1558, 1564 (Fed. Cir. 1996). (As pointed out by the court in *In re Angstadt*, 537 F.2d 498 at 504 (CCPA 1976), the key word is “undue”, not “experimentation”)

The factors that may be considered in determining whether a disclosure would require undue experimentation are set forth by *In re Wands*, 8 USPQ2d 1400 (CAFC

1988) at 1404 wherein, citing *Ex parte Forman*, 230 USPQ 546 (Bd. Apls. 1986) at 547 the court recited eight factors:

1) the quantity of experimentation necessary,

2) the amount of direction or guidance provided,

3) the presence or absence of working examples,

4) the nature of the invention,

5) the state of the prior art,

6) the relative skill of those in the art,

7) the predictability of the art, and

8) the breadth of the claims.

These factors are always applied against the background understanding that scope of enablement varies inversely with the degree of unpredictability involved. *In re Fisher*, 57 CCPA 1099, 1108, 427 F.2d 833,839, 166 USPQ 18, 24 (1970). Keeping that in mind, the *Wands* factors are relevant to the instant fact situation for the following reasons:

1. The nature of the invention, state and predictability of the art, and relative skill of those in the art

The invention relates to a method of modulating the binding of a $p56^{lck}$ molecule via an SH2 domain thereof to a corresponding cellular binding protein, or modulating the activity of a $p56^{lck}$ comprising administering a compound of formula I or a pharmaceutically acceptable salt thereof.

The relative skill of those in the art is high, generally that of an M.D. or Ph.D. The artisan using Applicants' invention would generally be a physician with a M.D. degree and several years of experience.

That factor is outweighed, however, by the unpredictable nature of the art. It is well established that "the scope of enablement varies inversely with the degree of unpredictability of the factors involved" and physiological activity is generally considered to be an unpredictable factor. See *In re Fisher*, 166 USPQ 18, at 24 (In cases involving unpredictable factors, such as most chemical reactions and physiological activity, the scope of enablement obviously varies inversely with the degree of unpredictability of the factors involved.), *Nationwide Chemical Corporation, et al. v. Wright, et al.*, 192 USPQ 95 (one skilled in chemical and biological arts cannot always reasonably predict how different chemical compounds and elements might behave under varying circumstances), *Ex parte Sudilovsky* 21 USPQ 2d 1702 (Appellant's invention concerns pharmaceutical activity. Because there is no evidence of record of analogous activity for similar compounds, the art is relatively unpredictable) *In re Wright* 27 USPQ2d 1510 (the physiological activity of RNA viruses was sufficiently unpredictable that success in developing specific avian recombinant virus vaccine was uncertain). As long as the specification discloses at least one method of making and using the claimed invention that bears a reasonable correlation to the entire scope of the claim, then the enablement requirement of 35 U.S.C. 112, 1st Paragraph is satisfied. *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). To that extent, if little is known in the prior art about the nature of the invention and the art is unpredictable, the specification

would need more detail as to how to make and use the invention in order to be enabling. See *Chiron Corp v. Genetech, Inc.*, 363 F.3d 1247, 1254, 70 USPQ2d 1321, 1326 (Fed. Cir. 2004) ("Nascent technology, however, must be enabled with a specific and useful teaching. The law requires an enabling disclosure for nascent technology because a person of ordinary skill in the art has little or no knowledge independent from the patentee's instruction. Thus, the public's end of the bargain struck by the patent system is a full enabling disclosure of the claimed technology."

2. The breadth of the claims

Whereas the claims are drawn to **modulating** the binding or activity of a $p56^{lck}$ molecule, the claims read on both **inhibiting** and **stimulating** the binding or activity of a $p56^{lck}$ molecule. The claimed compounds encompass a multitude (perhaps millions) of different compounds having chemically distinct substituents. Dependent Claim 13 recites 34 compounds, three of which read on formula (I) (Compounds 73, 276 and 285). Claim 19 limits the compounds of Claim 2 to those having a ClogP value of ≤ 5, a molecular weight of ≤ 500 Daltons, and ≤ 10 hydrogen bond donors and acceptors.

Exemplary of the breadth of compounds which are defined by formula (I) are the following 2 hypothetical compounds (Compounds “A” and "B”):



Hypothetical Compound "A" of Formula (I)



Hypothetical Compound "B" of Formula (I)

Whether any particular compounds encompassed by the claims would have any activity *in vitro*, let alone *in vivo*, would require synthesis and purification of the compound followed by testing in an *in vitro* or *in vivo* assay. Predicting, *a priori*, whether a given compound would modulate the binding or activity of a $p56^{lck}$ molecule does not appear to be possible.

3. The amount of direction or guidance provided and the presence or absence of working examples

Page 136 of the Specification states "It is proposed that compounds of the invention, by interacting with $p56^{lck}$, particularly with an SH2 domain thereof, modulate the kinase activity of the protein and/or modulate its ability to interact with a corresponding cellular binding protein, and thereby modulate immune responses, directly or indirectly, and neoplastic cell proliferation." The Specification discloses that 2 compounds of formula (I) (compounds 73 and 276) were tested in an *in vitro* assay for the inhibition of "p56 Lck SH2 domain association with phosphotyrosine-containing C-terminal ITAM2 peptide." According to the Specification, immunoblots from the assays (Figure 1-A) show compound 276 has "significant inhibitory activities at 100 μM [and] Figure 1 (panel B) shows a dose dependent inhibition of co-precipitation by the inhibitor 73; at 40 μM (lane 5) the compound significantly blocked p56 Lck association with the ITAM2 peptide. The 34 preferred compound identified herein were shown to have significant inhibitory activity at 100 μM….Of these, compounds 73 and 92 show strong inhibitory activity at 40 and 10 μM, respectively." (Pages 149-152) It is noted by the Examiner that only 3 (compounds 73, 276 and 285) of the 34 disclosed compounds

read on formula (I) and actual data is presented for only 2 of these compounds (73 and 276). Figure 2 of the disclosure present *in vitro* data for inhibition of ^{3}H-thymidine uptake in mixed lymphocyte culture. According to the Specification (page 152), 24 of the 34 identified compounds were tested, with 13 compounds showing inhibitory activity at 100 µM concentration (shown in Figure 2). It is disclosed that compound 73 was not tested at 100 µM because of solubility issues. It is noted that only 2 compounds (compounds 73 and 276) were presented as having activity. The Specification also discloses that 7 of the compounds showed "biphasic" activity, "where positive inhibitory activity is observed at higher concentration (100 µM) and negative inhibition (i.e. activation) occurs at lower concentrations (1 µM)."

4. The quantity of experimentation necessary

Because of the known unpredictability of the art (as discussed *supra*) and in the absence of experimental evidence commensurate in scope with the claims, the skilled artisan would not accept the assertion that the instantly claimed genus of compounds could be predictably used to inhibit all (or any) types of hyperproliferative cell growth encompassed by the claims.

Genentech Inc. vs. Nova Nordisk states, "[A] patent is not a hunting license. It is not a reward for a search but a compensation for its successful conclusion and 'patent protection' is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable" (42 USPQ 2d 1001, Fed. Circuit 1997).

Accordingly, the instant claims do not comply with the enablement requirement of 35 U.S.C. 112, first paragraph, since to practice the claimed invention a person of ordinary skill in the art would have to engage in undue experimentation, with no reasonable assurance of success.

Conclusion

16. Claims 1, 2, 7, 8, 10-13, 18, 19, 21 and 22 are rejected.

17. No claims are allowed.

18. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GREGG POLANSKY whose telephone number is (571)272-9070. The examiner can normally be reached on Mon-Thur 9:30 A.M. - 7:00 P.M. EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin H. Marschel can be reached on (571) 272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Gregg Polansky/
Examiner, Art Unit 1614

/James D Anderson/
Primary Examiner, Art Unit 1614